AFAnna Fleischer

Anna Fleischer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anna Fleischer has a total of 81 co-authors. Here are the top co-authors by number of shared publications:

  • Hermann Einsele

    Department of Internal Medicine II, Hematology and Oncology, University Hospital Würzburg, Würzburg, Germany

    5 shared publications
  • Imad Maatouk

    Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany

    5 shared publications
  • Imad Maatouk

    Department of Internal Medicine II, Section of Psychosomatics, Psychotherapy and Psychooncology, University Hospital Würzburg, Würzburg, Germany

    5 shared publications
  • Patrick-Pascal Strunz

    Department of Internal Medicine II, Rheumatology/Clinical Immunology, University Hospital Würzburg, Würzburg, Germany

    5 shared publications
  • Jessica Peter

    Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany

    4 shared publications
  • Johannes Waldschmidt

    Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany

    4 shared publications

Latest Publications

  • Open Access

    Beyond ICANS: Cellular and Molecular Mechanisms Linking CAR T-Cell Therapy to Long-Term Neurocognitive Outcomes

    by Anna Fleischer, Leo Rasche, Imad Maatouk

    Chimeric antigen receptor (CAR) T-cell therapy can cause acute immune effector cell-associated neurotoxicity syndrome (ICANS), but its delayed neurological and long-term cognitive effects remain incompletely understood. Existing reviews primarily address clinical syndromes or cognitive assessment. This narrative review provides a cross-timescale synthesis of preclinical, neuropathological, biomarker, imaging, and longitudinal clinical evidence linking systemic immune activation, neurovascular interfaces, and central nervous system (CNS) cellular responses. Human studies associate acute ICANS with endothelial and barrier dysfunction, compartmentalized inflammation, and selected astroglial or neuroaxonal injury markers. Persistent microglial reactivity, oligodendroglial alterations, and impaired neurogenesis have predominantly been demonstrated in mice; related human transcriptomic observations derive from CNS-tumor tissue and do not establish persistent injury in hematological CAR T-cell recipients. Prospective clinical cohorts show heterogeneous, often recovering cognitive trajectories rather than uniform long-term deterioration. Acute ICANS, delayed non-ICANSs, and longer-term cognitive outcomes are clinically distinguishable, although their biological separation remains incompletely established. Available treatment studies address predominantly acute toxicity and do not demonstrate prevention of persistent cognitive impairment. We propose testable neurovascular-to-glial and neuronal pathways and a baseline-anchored, multimodal longitudinal framework to connect biological responses and recovery with domain-specific cognitive outcomes.

  • Open Access

    Longitudinal psychosocial burden, quality of life, and digital supportive care preferences before and after CAR T-cell therapy: a prospective single-center observational study

    by Anna Fleischer, Sabine-Anna Bergert, Patrick-Pascal Strunz, Barbara Huber, Nadine Schassberger, Miriam Benz, Elisabeth Jentschke, Florian Eisele, Yoko Tamamushi, Hermann Einsele, et al.

    Background: Prospective studies of CAR T-cell therapy have described changes in patient-reported outcomes, but these are rarely examined alongside supportive care preferences and patients’ own accounts. We examined these components together across the treatment course. Methods: This prospective single-center study included adults scheduled for CAR T-cell therapy at a German tertiary hospital. Of 52 patients in the screening/recruitment log, 32 who completed at least three of four assessments formed the longitudinal cohort. Assessments occurred before treatment (T0), during post-infusion hospitalization (T1), at or around discharge (T2), and seven to eight weeks after discharge (T3). Standardized measures assessed quality of life, anxiety/depression, loneliness, fear of progression, somatic symptoms, and social support. Unadjusted generalized estimating equations examined longitudinal change; supportive care items were summarized descriptively and open-ended responses analyzed thematically. Results: The cohort included 17 male and 15 female participants; median age was 61.0 years (IQR 53.0-65.5), and 23/32 (71.9%) had multiple myeloma. Global health status/quality of life showed an overall time effect (p = 0.001), with the lowest mean at T2 and recovery by T3. Physical functioning was nominally lower at T2 (β = -14.450, p = 0.046); fatigue was nominally higher at T1 and T2 (β = 11.990, p = 0.015; β = 15.574, p = 0.008), and the QLQ-C30 summary score lower at T1 and T2 (β = -7.772, p = 0.006; β = -6.954, p = 0.035). Loneliness was nominally higher at T1 (β = 0.795, p = 0.009), whereas PHQ-4 scores changed little. Across timepoints, 60.0% to 70.0% considered post-discharge psycho-oncological support useful and 66.7% to 79.3% considered peer contact useful. Five themes concerned treatment uncertainty, physical decline, multidimensional support needs, accessible individualized digital support, and incomplete treatment understanding. Conclusions: Patient-reported physical and functional burden was greatest during hospitalization and around discharge and improved by seven to eight weeks after discharge. Brief anxiety/depression scores captured only part of participants’ support needs. The findings can inform co-design and prospective evaluation of longitudinal supportive care approaches without establishing intervention effectiveness.


  • Open Access

    Assessment of App Quality, User Experience, and Willingness to Recommend a Digital Therapeutic for Patients With Axial Spondyloarthritis: Subanalysis of a 12-Week Pretest-Posttest Intervention Study

    by Hannah Labinsky, Amelie Wuest, Patricia Possler, Tobias Heusinger, Maxime le Maire, Anna Fleischer, Karsten Sebastian Luetkens, Michael Gernert, Ottar Gadeholt, Robert Leppich, et al.

    Background: Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease affecting the axial skeleton that requires regular physical exercise in addition to pharmacotherapy. However, a significant proportion of patients do not exercise frequently enough. Axia is a digital therapeutic (DTx) that offers a solution by providing a disease-specific and patient-tailored home-based exercise program for patients with axSpA. The app combines structured exercise with patient education and disease management features and incorporates gamification and behavioral conditioning to promote user engagement. However, it has remained unclear how Axia is perceived and evaluated by patients. Objective: This study aimed to describe app quality, user experience, and willingness to recommend the app to others after 12 weeks of use by applying standardized questionnaires. Methods: This single-center study was conducted at an outpatient tertiary clinic. After 12 weeks of ad libitum app use, 27 participants with axSpA completed paper-based assessments of the user version of the Mobile App Rating Scale (uMARS; range 1-5) and the net promoter score (NPS; range −100% to +100%). Results: The mean overall uMARS app quality score was 4.44 (SD 0.43). Functionality received the highest mean score (4.54, SD 0.53), whereas information received the lowest (4.34, SD 0.49). The mean NPS was 9.52 (SD 0.75), corresponding to an overall NPS of 93%. The uMARS overall quality score correlated strongly with the NPS (ρ=0.57; P=.002). Except for physical therapy at baseline, no other baseline characteristic or therapeutic effect correlated with either the uMARS or NPS. Conclusions: Axia was perceived as a user-friendly DTx after 12 weeks of use. The findings support the acceptability of disease-specific DTx for patients with axSpA and the potential integration of DTx into routine care.

  • Open Access

    A four-domain framework for secondary immunodeficiency after CAR T-cell and T-cell-engaging antibody therapy

    by Anna Fleischer

    Chimeric antigen receptor (CAR) T-cell therapies and T-cell-engaging antibodies have transformed the treatment of hematologic malignancies but can induce prolonged, overlapping, and dynamically evolving immune deficits that are not adequately captured by hypogammaglobulinemia alone. Infection susceptibility reflects the interplay among the underlying disease and prior treatment, the immune-effector modality and therapeutic target, the predominant immune-deficit phenotype, and its evolution over time. We therefore propose a four-domain framework—Disease substrate, Drug and target, Deficit profile, and Dynamics—as a pragmatic structure for longitudinal characterization of secondary immunodeficiency after CAR T-cell and T-cell-engaging antibody therapy. The framework integrates myeloid, humoral, cellular, combined, and mucosal or epithelial barrier deficits with treatment-specific exposures and patterns of immune recovery, linking them to phenotype- and phase-adapted monitoring and prevention. We synthesize evidence on infection epidemiology, immune reconstitution, vaccination, antimicrobial prophylaxis, and immunoglobulin replacement while distinguishing established recommendations from practices supported mainly by observational data or expert consensus. A dynamic, phenotype-guided approach may improve targeting of preventive interventions while limiting avoidable prophylactic exposure. Priority research needs include standardized immune and infection end points, prospective longitudinal immune phenotyping, externally validated dynamic risk models, and comparative-effectiveness studies of immunoglobulin replacement, response-adapted extension of dosing intervals for T-cell-engaging antibodies, and antimicrobial prophylaxis.


  • Open Access

    Gustatory dysfunction under talquetamab therapy in multiple myeloma: a cross-sectional study of patient-reported course, nutritional changes, and quality of life

    by Anna Fleischer, Carolin Burger, Magdalena Roll, Franziska Panther, Patrick-Pascal Strunz, Jessica Peter, Sofie-Katrin Kadel, Anja Gesierich, Julia Mersi, Johannes Waldschmidt, et al.

    The purpose of this study is to characterize patient-reported taste disturbances, recalled symptom course, nutritional changes, and quality of life in patients with relapsed/refractory multiple myeloma treated with talquetamab. This single-center cross-sectional study combined taste-strip testing with a study-specific questionnaire, EORTC QLQ-C30, and PHQ-4 in 32 patients. Analyses used recorded aggregate correct-identification counts without a normative hypogeusia classification. Symptom timing and changes since treatment initiation were recalled at one assessment. All patients reported taste disturbances during therapy. The median identification count was 2.5 (interquartile range 0.75–7.25); eight patients had no correct identifications. Twenty-three (71.9%) described onset within 14 days. Current appetite reduction was reported by 20 patients (62.5%), whose mean identification count was lower than that of the other 12 patients (2.45 versus 7.83; mean difference − 5.38, 95% confidence interval − 8.20 to − 2.57; p = 0.0006). Sixteen patients (50.0%) reported directional weight loss, with a median loss of 4.5 kg. Ten (31.3%) had considered stopping talquetamab; seven explicitly cited taste disturbance. Mean global health status was 50.5/100 and correlated with identification count ( r = 0.406; p = 0.021). Taste disturbances co-occurred with substantial nutritional concerns. Lower taste-identification counts were associated with current appetite reduction and lower global health status. The findings support attention to taste-related burden but do not establish causality, sustained recovery, or effects on adherence. Prospective evaluations of supportive care are needed.

  • Open Access

    Patient preferences for treatment‑free intervals in multiple myeloma: mixed‑methods insights on monitoring trade‑offs and supportive care improvements

    by Anna Fleischer, Mohammad Barakat, Jessica Peter, Sofie-Katrin Kadel, Christine Riedhammer, Patrick-Pascal Strunz, Julia Mersi, Johannes Waldschmidt, K. Martin Kortüm, Hermann Einsele, et al.

    Purpose: Continuous and maintenance therapy remains central to multiple myeloma (MM) care, but repeated treatment-related healthcare encounters may impose physical, psychosocial, and logistical burden. We explored patient preferences regarding intervals between active treatment contacts, monitoring trade-offs, and opportunities to improve inpatient and outpatient care. Methods: A 12-month, single-center mixed-methods survey was conducted among 100 patients with MM at a German tertiary center. The survey assessed the perceived importance and preferred length of treatment-free intervals (TFIs), monitoring perceptions, relapse-risk trade-offs, inpatient stressors, and care-improvement proposals. Quantitative responses were summarized with item-specific denominators and exact 95% confidence intervals (CIs). Free-text responses underwent inductive content analysis by two independent raters and mixed-methods integration. Results: Intervals between inpatient treatments were rated 10/10 by 49/100 participants (49.0%; 95% CI 38.9–59.2) and 0/10 by 9/100 (9.0%; 95% CI 4.2–16.4). The most frequently reported inpatient stressors were separation from family (27.0%), treatment-related symptoms or side effects (23.0%), and fatigue (17.0%). Regular check-ups were reassuring for 77/100 (77.0%; 95% CI 67.5–84.8) and burdensome for 13/100 (13.0%; 95% CI 7.1–21.2). Seven of 100 participants (7.0%; 95% CI 2.9–13.9) explicitly accepted higher relapse risk for longer TFIs. Preferred minimum interval length was heterogeneous; 39/99 (39.4%; 95% CI 29.7–49.7) preferred > 8 weeks. Qualitative narratives emphasized recovery, autonomy, restoration of routines, and modifiable care-process factors. Conclusion: Patients frequently valued intervals between active treatment contacts for recovery, while monitoring was predominantly reassuring. These descriptive findings do not establish the safety or clinical appropriateness of longer TFIs but support prospective evaluation of preference-sensitive scheduling and monitoring.


  • Open Access

    Natural Taste Modulators and Microbiome-Aware Nutritional Support for Immunotherapy-Associated Dysgeusia: A Translational Perspective for Precision Supportive Cancer Care

    by Anna Fleischer

    Dysgeusia is a clinically consequential, but still under-standardized, toxicity of cancer treatment. In the immunotherapy era, taste disturbances are increasingly relevant for patients receiving immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapies and T-cell-redirecting bispecific antibodies, with G protein-coupled receptor family C group 5 member D (GPRC5D)-directed treatment in multiple myeloma representing a particularly instructive high-burden model. We performed a structured critical narrative review with evidence mapping. PubMed/MEDLINE was searched from database inception to June 2026, complemented by citation tracking in Google Scholar, ClinicalTrials.gov searches and guideline documents relevant to oncology nutrition, oral supportive care and cancer-related taste dysfunction. Search concepts covered cancer-related dysgeusia, immunotherapy-associated oral toxicity, GPRC5D/talquetamab-associated dysgeusia, oncology nutrition, oral–gut microbiome biology, natural taste modulators and miraculin-based interventions. Dysgeusia can reduce appetite, food enjoyment, dietary diversity and protein energy intake, thereby contributing to weight loss, malnutrition risk, distress, social withdrawal and, in severe cases, treatment modification or discontinuation. Available evidence is heterogeneous: general cancer-treatment-associated dysgeusia is supported by broader observational and interventional literature; immunotherapy-associated dysgeusia is less systematically characterized; and GPRC5D/talquetamab-associated dysgeusia represents the most clinically visible and target-specific immunotherapy-associated phenotype. Emerging pilot data suggest that dried miracle berry or miraculin-containing products may improve selected taste perception and nutritional parameters in cancer-related dysgeusia, but direct evidence in immunotherapy-associated dysgeusia is not yet established. We, therefore, propose a claim-disciplined precision supportive-care framework integrating systematic taste phenotyping, early nutritional risk assessment, oral health evaluation, microbiome-aware but hypothesis-generating endpoints, individualized flavor and texture adaptation, cautious use of natural taste modulators in selected patients and iterative monitoring of patient-centered outcomes. Future trials should test whether dysgeusia-focused nutritional and taste-modulating supportive care interventions can improve intake, quality of life and treatment persistence without compromising immunotherapy safety or efficacy.


  • Open Access

    The cardio–neuro–psycho–oncological axis in modern cellular and bispecific antibody therapies: A perspective on brain–heart interactions, autonomic vulnerability, and patient-centered monitoring

    by Anna Fleischer

    Chimeric antigen receptor T-cell therapy and T-cell-engaging bispecific antibodies have transformed hematologic oncology, but their toxicities frequently cross organ-based boundaries. Cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS), cardiovascular stress, autonomic dysregulation, sleep disruption, fatigue, and psychological distress may overlap in time and amplify one another. This perspective proposes a cardio–neuro–psycho–oncological framework for immune effector therapy. The model integrates inflammatory and endothelial activation, neurological and cognitive vulnerability, cardiovascular and autonomic regulation, and patient-reported burden. Rather than replacing established CRS and ICANS grading, it supports baseline risk stratification, longitudinal multimodal monitoring, actionable escalation pathways, and survivorship-oriented follow-up. It further distinguishes essential, recommended, and exploratory monitoring components and emphasizes therapy-specific monitoring needs, privacy-preserving implementation, workload-sensitive workflows, and prospective validation. Prospective studies should evaluate whether combined brain–heart–autonomic and patient-reported monitoring improves toxicity prediction, functional recovery, and quality of life as immune effector therapies move into broader patient populations.